EUVIMEDEUVIMED entdecken
Leitlinie

Clinical implications and guidelines for CKD in type 2 diabetes

Rong M Zhang iD, Frederik Persson iD, Janet B McGill, Peter Rossing iD

Nephrology Dialysis Transplantation · 28.02.2023 · 38 (3) · 542-550

DOI: 10.1093/ndt/gfac285 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 20.10.2022. Verfasst von Rong M Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St Louis, MO, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: American Heart Association, Novo Nordisk, Dexcom.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic kidney disease (CKD) is a complication of type 2 diabetes (T2D) with high morbidity and mortality. The prevalence of CKD in T2D is increasing due to rising numbers of persons with T2D. Multiple clinical trials have been conducted testing novel therapies to reduce the progression of CKD, cardiovascular morbidity, in particular hospitalization for heart failure, and mortality. Results of these clinical trials have informed guidelines for the management of CKD in T2D.

Methods

The epidemiology of CKD in T2D and the process of guideline writing, including data gathering, grading and consensus development, were reviewed. Recent guidelines for the management of CKD in T2D that include recent renal outcome clinical trials are reported, along with supporting evidence.

Results

All current guidelines recommend annual screening for CKD, control of blood pressure and glucose, although the target levels and background therapy recommendations vary. Renin–angiotensin system (RAS) inhibition is uniformly recommended. Sodium-glucose cotransporter-2 (SGLT2) inhibition with proven agents is recommended by all guidelines, with minor variations in suggested estimated glomerular filtration rate and albuminuria levels. Finerenone, the first nonsteroidal mineralocorticoid receptor antagonist with renal outcome data, is recommended by the most recent guideline available.

Conclusions

Current guidelines continue to recommend screening for CKD, blood pressure control using RAS inhibition as first-line therapy, and glucose control. SGLT2 inhibition and finerenone are recent additions to current guidelines to improve CKD outcomes in T2D, based on robust clinical trial data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetic NephropathiesRenal Insufficiency, ChronicHumansSodium-Glucose Transporter 2Glucose

Stichwörter der Autor:innen

chronic kidney diseasediabetesdiabetic kidney diseasediabetic nephropathyguidelines

Substanzen

Sodium-Glucose Transporter 2Glucose

Autor:innen und Institutionen

  • Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St Louis, MO, USA.
  • Steno Diabetes Center Copenhagen, Borgmester Ib Juuls Vej 83, Herlev, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Rong M Zhang, Frederik Persson, Peter Rossing

Förderung

  • American Heart Association
  • Novo Nordisk
  • Dexcom
  • Medtronic
  • Beta Bionics
  • JDRF
  • Washington University
  • Burroughs Wellcome Fund

Zitieren

APA

Zhang, R. M., Persson, F., McGill, J. B., & Rossing, P. (2023). Clinical implications and guidelines for CKD in type 2 diabetes. Nephrology Dialysis Transplantation, 38(3), 542-550. https://doi.org/10.1093/ndt/gfac285

Vancouver

Zhang RM, Persson F, McGill JB, Rossing P. Clinical implications and guidelines for CKD in type 2 diabetes. Nephrology Dialysis Transplantation. 2023;38(3):542-550. doi:10.1093/ndt/gfac285

BibTeX
@article{Zhang2023,
  author = {Zhang, Rong M and Persson, Frederik and McGill, Janet B and Rossing, Peter},
  title = {Clinical implications and guidelines for CKD in type 2 diabetes},
  journal = {Nephrology Dialysis Transplantation},
  year = {2023},
  volume = {38},
  number = {3},
  pages = {542--550},
  doi = {10.1093/ndt/gfac285}
}
Kostenlos starten →